|Last Price||Today's Change||52-Week Range||Trading Volume|
|43.63||0.02 (+0.05%)||41.91 - 56.73||10.0 million (Above Avg)|
Market data as of 4:04PM 10/21/14. Quotes are delayed by at least 15 min.
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S.
10/20/2014 9:00 AM ET
GSK receives FDA approval of an additional Promacta® (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)
08/26/2014 3:52 PM ET
Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection
08/25/2014 9:00 AM ET